全文获取类型
收费全文 | 78834篇 |
免费 | 6080篇 |
国内免费 | 1988篇 |
专业分类
耳鼻咽喉 | 720篇 |
儿科学 | 3205篇 |
妇产科学 | 1759篇 |
基础医学 | 12458篇 |
口腔科学 | 1036篇 |
临床医学 | 8544篇 |
内科学 | 10075篇 |
皮肤病学 | 844篇 |
神经病学 | 3984篇 |
特种医学 | 2139篇 |
外国民族医学 | 7篇 |
外科学 | 7106篇 |
综合类 | 11142篇 |
现状与发展 | 8篇 |
预防医学 | 9953篇 |
眼科学 | 522篇 |
药学 | 7699篇 |
58篇 | |
中国医学 | 2230篇 |
肿瘤学 | 3413篇 |
出版年
2024年 | 61篇 |
2023年 | 1092篇 |
2022年 | 1861篇 |
2021年 | 3400篇 |
2020年 | 3311篇 |
2019年 | 2467篇 |
2018年 | 2420篇 |
2017年 | 2583篇 |
2016年 | 2740篇 |
2015年 | 2762篇 |
2014年 | 5048篇 |
2013年 | 5263篇 |
2012年 | 4520篇 |
2011年 | 4962篇 |
2010年 | 3881篇 |
2009年 | 3754篇 |
2008年 | 3683篇 |
2007年 | 3694篇 |
2006年 | 3382篇 |
2005年 | 2937篇 |
2004年 | 2723篇 |
2003年 | 2593篇 |
2002年 | 1626篇 |
2001年 | 1560篇 |
2000年 | 1321篇 |
1999年 | 1207篇 |
1998年 | 1067篇 |
1997年 | 945篇 |
1996年 | 895篇 |
1995年 | 961篇 |
1994年 | 896篇 |
1993年 | 783篇 |
1992年 | 771篇 |
1991年 | 613篇 |
1990年 | 583篇 |
1989年 | 508篇 |
1988年 | 463篇 |
1987年 | 408篇 |
1986年 | 364篇 |
1985年 | 496篇 |
1984年 | 420篇 |
1983年 | 282篇 |
1982年 | 301篇 |
1981年 | 252篇 |
1980年 | 207篇 |
1979年 | 178篇 |
1978年 | 153篇 |
1977年 | 119篇 |
1976年 | 101篇 |
1974年 | 60篇 |
排序方式: 共有10000条查询结果,搜索用时 19 毫秒
11.
12.
目的 探讨血清微小RNA-210(mircoRNA-210,miR-210)与新生儿呼吸窘迫综合征(neonatalrespiratory distress syndrome,NRDS)严重程度和预后的关系。
方法 收集NRDS患儿104例,根据预后分为生存组与死亡组。所有新生儿根据首次胸部X线片结果与病情严重程度分为轻度组(Ⅰ级、Ⅱ级)与重度组(Ⅲ级、Ⅳ级)。比较死亡组与生存组患儿一般资料,轻度组与重度组血清miR-210水平与新生儿急性生理学评分围生期补充Ⅱ(perinatal supplement of acute physiological score for neonates Ⅱ,SNAPPE-Ⅱ)评分。绘制ROC曲线分析血清miR-210水平对NRDS患儿死亡的预测价值。采用Spearman相关性分析NRDS发生与血清miR-210的相关性。
结果 根据预后分组,104例患儿中预后较好81例(77.88%),死亡23例(22.12%)。生存组miR-210水平、SNAPPE-Ⅱ评分低于死亡组(P<0.05);2组性别、胎龄、出生体重、母亲年龄、病因、剖宫产、双胎、羊水异常差异无统计学意义(P>0.05)。按照胸部X线片表现分组,104例患儿轻度患儿73例,重度患儿31例。轻度组miR-210水平、SNAPPE-Ⅱ评分低于重度组(P<0.05)。NRDS发生与血清miR-210水平呈正相关(r=0.638,P<0.001)。血清miR-210与SNAPPE-Ⅱ评分呈正相关(r=0.513,P<0.05)。血清miR-210的最佳分界值为16.71 ng/L时,曲线下面积为0.763,OR=0.846,95%CI:0.892~1.064,敏感度为82.61%,特异度为86.42%。结论 血清miR-210水平升高与NRDS病情严重程度以及预后密切相关,血清miR-210水平与NRDS病情程度呈正相关性,当血清miR-210临界值为16.71 ng/L时对评估NRDS患儿预后具有较高价值。 相似文献
13.
《Seminars in perinatology》2022,46(7):151635
The Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NRN) maintains a database of extremely preterm infants known as the Generic Database (GDB). Begun in 1987, this database now includes more than 91,000 infants, most of whom are extremely preterm (<29 weeks gestation). The GDB has been the backbone of the NRN, providing high quality, prospectively collected data to study the changing epidemiology of extreme prematurity and its outcomes over time. In addition, GDB data have been used to generate hypotheses for prospective studies and to develop new clinical trials by providing information about the numbers and characteristics of available subjects and the expected event rates for conditions and complications to be studied. Since its inception, the GDB has been the basis of more than 200 publications in peer-reviewed journals, many of which have had a significant impact on the field of neonatology. 相似文献
14.
15.
《Drug discovery today》2022,27(5):1367-1380
The tremendous advances in genomics, recombinant DNA technology, bioengineering and nanotechnology, in conjunction with the development of high-end computations, have been instrumental in the process of rational design of peptide-based vaccines. The use of peptide vaccines was limited owing to their inherent instability when systemically administered; however, advanced formulation techniques have been developed for their systemic delivery, thereby overcoming their degradation, clearance, cellular uptake and off-target effects. With the rise of sophisticated immunological predictors and experimental techniques, several methodological advances have occurred in this field. This review examines contemporary methods to identify and optimize epitopes, engineer their immunogenic properties and develop their safe and efficient delivery into the host. 相似文献
16.
《Vaccine》2022,40(24):3380-3388
BackgroundWe evaluated the safety and immunogenicity of NVX-CoV2373, a recombinant SARS-CoV-2 nanoparticle vaccine, in healthy Japanese participants.MethodsThis phase 1/2, randomized, observer-blind, placebo-controlled trial conducted in Japan (two sites), enrolled healthy Japanese adults aged ≥ 20 years with no history/risk of SARS-CoV-2 infection and no prior exposure to other approved/investigational SARS-CoV-2 vaccines or treatments. Participants were stratified by age (< 65 or ≥ 65 years) and randomized to receive two doses of either NVX-CoV2373 (5 μg SARS-CoV-2 rS; 50 μg Matrix-M1) or placebo, 21 days apart. Primary outcomes were safety and immunogenicity assessed by serum IgG antibody levels against SARS-CoV-2 rS protein on day 36. Herein, we report the primary data analysis at 4 weeks after the second dose, ahead of 12-month follow-up completion (data cut-off: 8 May 2021).ResultsBetween 12 February 2021 and 17 March 2021, 326 subjects were screened, and 200 participants enrolled and randomized: NVX-CoV2373, n = 150; placebo, n = 50. Solicited adverse events (AEs) through 7 days after each injection occurred in 121/150 (80.7%) and 11/50 (22.0%) participants in the NVX-CoV2373 and placebo arms, respectively. In the NVX-CoV2373 arm, tenderness and injection site pain were the most frequently reported solicited AEs after each vaccination, irrespective of age. Robust immune responses occurred with NVX-CoV2373 (n = 150) by day 36: IgG geometric mean fold rise (95% confidence interval) 259 (219, 306); seroconversion rate 100% (97.6, 100). No such response occurred with placebo (n = 49).ConclusionTwo doses of NVX-CoV2373 given with a 21-day interval demonstrated acceptable safety and induced robust anti-SARS-CoV-2 immune responses in healthy Japanese adults. Funding: Takeda Pharmaceutical Company Limited and Japan Agency for Medical Research and Development (AMED). ClinicalTrials.gov identifier: NCT04712110. 相似文献
17.
背景 结核病是导致人免疫缺陷病毒/获得性免疫缺陷综合征(HIV/AIDS)患者死亡的首要原因,而HIV感染也是导致结核潜伏感染(LTBI)发展为结核病的主要危险因素。因此,对HIV/AIDS患者进行LTBI筛查和治疗是预防该类人群结核病的发生从而减少其死亡的重要举措。 目的 对宁夏回族自治区银川市市区内HIV/AIDS患者进行LTBI筛查,并分析其影响因素,识别高危人群,为HIV/AIDS患者结核病的预防性治疗提供科学依据。 方法 选取2021年3—8月于宁夏回族自治区银川市市区内定点管理单位治疗的546例HIV/AIDS患者为研究对象。通过现场问卷调查及查阅患者管理档案的方式收集HIV/AIDS患者的一般资料,其中一般人口学特征包括性别、年龄、民族、学历、婚姻状况、家庭人均年收入、职业类型、体质指数(BMI)、吸烟情况、饮酒情况等;临床资料包括慢性病患病情况、与结核病患者密切接触情况、HIV/AIDS确诊时长、抗病毒治疗时长、合并其他感染情况、近期CD4+ T淋巴细胞计数(CD4)等。通过结核菌素皮肤试验(TST)对研究对象进行LTBI筛查,根据TST结果将546例HIV/AIDS患者分为非LTBI组(TST阴性413例)和LTBI组(TST阳性133例)。比较两组患者的一般资料,采用多因素Logistic回归分析探讨HIV/AIDS患者发生LTBI的影响因素,并利用R软件建立限制性立方样条模型拟合CD4与LTBI风险之间的量效关系。 结果 银川市市区内HIV/AIDS患者的TST阳性率为24.4%。已婚〔OR=0.544,95%CI(0.321,0.922),P<0.05〕是HIV/AIDS患者发生LTBI的保护因素;吸烟〔OR=1.919,95%CI(1.213,3.037),P<0.05〕、与结核病患者有过密切接触〔OR=11.100,95%CI(2.889,42.648),P<0.05〕是HIV/AIDS患者发生LTBI的危险因素。限制性立方样条模型拟合结果显示,HIV/AIDS患者的CD4与LTBI风险呈近似"n"形的非线性关系(非线性检验χ2=29.080,P<0.001)。 结论 应重点关注HIV/AIDS患者中未婚、吸烟、与结核病患者有过密切接触人群LTBI的发生情况,并及时进行预防性治疗;对于CD4较低的患者,建议采用多种方法进行LTBI筛查。 相似文献
18.
Jerzy Klijanienko MD PhD Béatrix Cochand-Priollet MD PhD Wiktoria Król-Cieciorowska Michał Jeleń MD PhD Danijela Vrdoljak-Mozetič MD PhD 《Cancer cytopathology》2022,130(7):488-490
The 43rd European Congress of Cytology in Wrocław, Poland, was held as a hybrid meeting in the Fall of 2021. After nearly 2 years without in-person cytology conferences, the 43rd Congress represents 1 of the first major international scientific meetings to occur during the severe acute respiratory syndrome-coronavirus 2 pandemic. Since March 2020, the pandemic situation substantially modified the organization of scientific meetings because of both domestic and international travel restrictions, new health standards, and concern among participants, resulting in new alternative forms of virtual conferencing. Cancer (Cancer Cytopathol) 2022;130:000-000. ; 相似文献
19.
ObjectiveTo investigate the feasibility of transnasal heated humidified high flow nasal cannula oxygen therapy (HFNC) in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with respiratory failure in elderly patients. MethodsA total of 176 elderly patients with AECOPD complicated with respiratory failure who were hospitalized at Peking University Shougang Hospital from December 2016 to January 2022 were enrolled, including 82 patients in an HFNC group and 94 patients in an NPPV group. After treatment, pulse oxygen saturation (SPO2), arterial partial pressure of carbon dioxide (PaCO2), oxygenation index (OI), respiratory rate (RR), heart rate (HR), mean arterial pressure (MAP), comfort score, discharge rate, rate of endotracheal intubation, rate of transfer to intensive care unit (ICU), and mortality were compared between the two groups. The independent sample t-test was used for comparison between the two groups. Statistical data are expressed in percentage or number of cases and the χ2 test was used for their comparisons. ResultsThe SPO2 values at 30 min, 1 h, and 6 h were significantly higher in the HFNC group than in the NPPV group (t=-2.049,-2.618, and -3.314, P=0.043, 0.010, and 0.001, respectively). SPO2 before discharge was significantly lower than that of the NPPV group (t=2.162, P=0.033), but OI at each time point and before discharge had no statistical significance (P>0.05). MAP at 6 h was significantly higher in the HFNC group than in the NPPV group (t=-2.209, P=0.029), but within the normal range. HRs at 2 h and 3 h in the HFNC group were significantly higher than those of the NPPV group (t=-2.199 and -2.336, P=0.030 and 0.021, respectively). There were no significant differences in RR, HR, or MAP between the two groups at other time points and before discharge (P>0.05). There was no significant difference in PaCO2 between the two groups (P>0.05). Comfort score in the HFNC group was significantly higher than that of the NPPV group (t=-46.807, P<0.001). There were no significant differences in discharge rate, ICU transfer rate, endotracheal intubation rate, and mortality between the two groups (P>0.05). ConclusionHFNC is as effective as NPPV in treating elderly patients with AECOPD complicated with type Ⅰ or mild type Ⅱ respiratory failure, and HFNC is more comfortable than NPPV. 相似文献
20.
Analytical procedure for detection and quantification of etaqualone in human blood and urine using GC–MS/MS was established and applied to authentic human samples obtained from volunteers. A liquid–liquid extraction method was employed. Each 1.0 mL of blood or urine was alkalized and extracted with diethyl ether. The solvent layer was evaporated to dryness and reconstituted with methanol then analyzed by GC–MS/MS. linear relationships within the concentration range of 1–100 ng/mL were obtained in calibrators for both blood and urine, demonstrating correlation coefficients values being>0.999. For blood and urine samples, the intra-day assay precision and accuracy values are each less than 3.65%, 7.13%, and 6.02%, 9.12%; those values of the inter-day assay are each less than 1.82%, 6.74%, and 3.99%, 7.41%. The extraction recovery rates for etaqualone ranged from 98.7% to 106%. The lower limit of quantifications was 1.0 ng/mL in both blood and urine. Stabilities of etaqualone in blood and urine were satisfactory under various temperatures within 15 days. 8.51 and 2.06 ng/mL of etaqualone in blood and urine were detected at 4 h later oral ingestion; 6.91 and 3.94 ng/mL of etaqualone were also detected 30 min and 2 h later smoking from blood and urine. 相似文献